Food Ingredients and Flavorings Sector Outlook — September 2026
This report maps the Food Ingredients and Flavorings sector by business model, showing how specialty ingredient chemistry, packaged-food brands and other operating models compare on forward valuation, growth and margin. Built for owners, management teams and boards weighing where to invest in capability and mix.
For information only. Not an appraisal or a fairness opinion.
What moved since: Food Ingredients and Flavorings M&A update, 14–28 September 2026
Key figures
- Sector Median Valuation
- 12.8x
- EV/EBITDA (CY2027E), rated companies
- Specialty Chemistry Median
- 15.6x
- EV/EBITDA (CY2027E), specialty chemistry names
- Packaged-Food Brands Median
- 10.2x
- EV/EBITDA (CY2027E), packaged-food brand owners
- Precedent Deal Multiple, High End
- 20.3x
- LTM EV/EBITDA at announcement, disclosed transactions
Read the report
1 / 22 · CONSUMER STAPLES › FOOD, BEVERAGE AND TOBACCO › FOOD INGREDIENTS AND FLAVORINGS
Executive summary
Specialty ingredient chemistry trades at a median EV/EBITDA (CY2027E) of 15.6x, well above the 10.2x for packaged-food brand owners. Names clearing both the growth and margin thresholds sit at 15.0x versus 6.9x for those below both. Precedent transactions with disclosed terms span 7.8x to 20.3x, consistent with buyers pricing strategic fit deal by deal. The agenda is to deepen specified solutions and convert brief wins into durable price/mix.
Key findings
- Specialty chemistry commands a higher forward multiple than packaged-food brands.
- Faster growth and higher margin together separate the top of the valuation range.
- Precedent deal multiples span 7.8x to 20.3x, reflecting deal-specific strategic fit.
- Valuation tracks growth, margin and specified-solutions quality, not the sector label.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
CONSUMER STAPLES › FOOD, BEVERAGE AND TOBACCO › FOOD INGREDIENTS AND FLAVORINGS
This is the cover page introducing the Food Ingredients and Flavorings sector outlook as of September 2026.
We open with the Food Ingredients and Flavorings sector as of September 2026, valued on EV/EBITDA (CY2027E) consensus. This report shows where market value sits across specialty ingredient chemistry, adjacent brand owners and other operating models — the split that drives everything that follows.
Everything on this page
CONSUMER STAPLES › FOOD, BEVERAGE AND TOBACCO › FOOD INGREDIENTS AND FLAVORINGS Food Ingredients and Flavorings: Value Splits by Mix This report shows where market value sits across specialty ingredient chemistry, adjacent brand owners and other operating models. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This slide lists the report's five sections plus the appendix.
We give you the map before the detail: five sections plus the appendix, starting with the bottom line so the whole story lands even if you stop there. From here we move into the landscape, valuation and situations, precedent transactions and the strategic agenda — each building on the last, so what matters compounds as we go.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Capability and Earnings Quality Separate the Market 02 The Landscape The Sector Label Spans Businesses with Different Economics 03 Valuation & Situations The Premium End Reflects Durability Beyond the Forecast 04 Precedent Transactions Precedent Transactions Favour Buyers with Asset-Specific Conviction 05 Strategic Implications Strengthen the Operating Proof Behind Mix, Margin and Retention 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Food Ingredients and Flavorings Split Between Specialty Chemistry and Adjacent Brand Models
This slide states the core finding — value splits between specialty chemistry and adjacent brand models.
The sector label covers businesses with materially different economics, and that split is the story of this deck. Specialty ingredient chemistry sits toward the top of the valuation range, while packaged-food brand owners sit lower, on an EV/EBITDA (CY2027E) basis as of September 2026. Growth and margin quality further separate the peer set within that split. So what: where a business sits on mix, growth and margin determines where it sits in the valuation range — and that is the lens for everything from here.
Everything on this page
01 · THE BOTTOM LINE Food Ingredients and Flavorings Split Between Specialty Chemistry and Adjacent Brand Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Specialty Chemistry Sits Above Packaged-Food Brands The four specialty chemistry names with estimates sit at 15.6x, against 10.2x for the three packaged-food brand owners with estimates. The difference is consistent with greater value being placed on specified solutions, application capability and spec-in positions. 2 Faster Growth Travels with a Higher Forward Valuation Among eight names with estimates, the four at or above 4% revenue growth sit at 12.9x; the four below sit at 10.9x. The observed premium supports close attention to brief wins, formulation mix and customer adoption. 3 The Names Clearing Both the Growth and the Margin Bar Sit at the Top of the Valuation Range Among eight names with estimates, the three above both the growth and 18% margin lines sit at 15.0x, while the three below both sit at 6.9x. Price/mix, fixed-cost absorption and raw-material recovery remain central to that positioning. 4 Precedent Transactions Leave Room for Asset-Specific Conviction Disclosed EV / EBITDA in the transaction record spans 7.8x to 20.3x. That range suggests buyers distinguish carefully among capability depth, earnings quality and strategic fit. 12.8x Sector median EV/EBITDA CY2027E consensus · 8 rated of 12 companies 16.8x Premium end EV/EBITDA vs 5.8x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 15 Transactions with disclosed terms 42 recorded in this tier · 1 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces the section on how the sector label spans different business models.
The next pages show that the sector label spans businesses with different economics — specified ingredient solutions sit beside packaged-food brands and other operating models. So what: understanding which model a business runs is the first step to reading its valuation correctly.
Everything on this page
SECTION 02 02 THE LANDSCAPE The Sector Label Spans Businesses with Different Economics Specified ingredient solutions sit beside packaged-food brands and adjacent operating models. 02 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Specified Ingredient Chemistry Sits Toward the Upper End of the Valuation Range
This slide groups the 12 approved companies by business segment and shows median EV/EBITDA (CY2027E) per group.
Grouping the 12 approved companies by segment, specified ingredient chemistry sits toward the upper end of the valuation range. That pattern holds across the rated names, not just a single company. So what: the market is already pricing business model, not just sector membership — a signal worth acting on when framing any commercial conversation.
Everything on this page
02 · MARKET MAP Specified Ingredient Chemistry Sits Toward the Upper End of the Valuation Range 12 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 ADJACENT: PACKAGED FOOD BRAND OWNERS (FORMULATION CUSTOMERS) 5 cos median 10.2x The Kraft Heinz (KHC) Nomad Foods (NOMD) Westrock Coffee (WEST) The Hain (HAIN) Beyond Meat (BYND) These formulation customers provide an offtake-side view shaped by brand economics, procurement pressure and category demand. SPECIALTY FOOD INGREDIENT CHEMISTRY — COLORS, ENZYMES AND TEXTURANTS 4 cos median 15.6x International (IFF) Sensient (SXT) Balchem (BCPC) Alto Ingredients (ALTO) These businesses compete through formulation know-how, application support, qualification barriers and specified performance. ADJACENT MODELS 3 cos 10.7x · 1 rated Keurig Dr Pepper (KDP) Domino's Pizza (DPZ) Vital Farms (VITL) These names broaden the market view across beverages, foodservice and primary sourcing models.
- 0602 · LANDSCAPE
Valuations Track the Business Model More Closely than the Shared Sector Label
This slide compares valuations across segments to show they track business model more than the shared sector label.
Segment by segment, valuations track the business model far more closely than the shared Food Ingredients and Flavorings label would suggest. The medians on rated names diverge by what a business actually does — specified solutions versus packaged brands versus other models. So what: any conversation about value in this sector has to start with which model the business runs, not the label on the sector map.
Everything on this page
02 · LANDSCAPE Valuations Track the Business Model More Closely than the Shared Sector Label Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Adjacent: packaged food brand owners (formulation customers) 5 42% 10.2x The Kraft Heinz Company (KHC) · Nomad Foods Limited (NOMD) · +3 more Brands anchor customer demand. Packaged-food owners represent the customer side of formulation and reformulation. Their economics reflect brand strength, category volume and procurement choices as much as ingredient capability. Specialty food ingredient chemistry — colors, enzymes and texturants 4 33% 15.6x International Flavors & Fragrances Inc. (IFF) · Sensient Technologies Corporation (SXT) · +2 more Technical capability supports differentiation. Color, enzyme and texturant suppliers compete through spec-in positions, application labs and co-creation. Qualification cycles and on-label approvals can support durable customer relationships. Adjacent models 3 25% 10.7x n=1 Keurig Dr Pepper Inc. (KDP) · Domino's Pizza, Inc. (DPZ) · +1 more Adjacent economics widen the frame. Beverage, foodservice and sourcing models expose different demand, capital and margin structures. They are useful context but require care when compared with specialist ingredient houses.
- 07SECTION 03
03
This divider introduces the section on public market valuation and the premium end of the range.
The premium end of the range reflects durability that goes beyond the forecast period — the valuation range stays wide even after expected growth is credited. So what: the next pages show exactly where that gap comes from.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium End Reflects Durability Beyond the Forecast The forward valuation range remains wide after expected growth is already credited. 03 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Top of the Valuation Range Trades Well Clear of the Bottom, Even Once Forecast Growth Is Credited
This slide ranks all 8 rated companies by EV/EBITDA (CY2027E) against the sector median of 12.8x.
Across all 8 rated companies, the top of the valuation range trades well clear of the bottom, even once forecast growth is already credited, against a sector median of 12.8x. The spread persists after normalizing for the same basis and the same forecast year. So what: the market is pricing something beyond near-term growth — durability and quality of earnings — and that is worth naming explicitly in any valuation conversation.
Everything on this page
03 · PUBLIC MARKET VALUATION The Top of the Valuation Range Trades Well Clear of the Bottom, Even Once Forecast Growth Is Credited EV / EBITDA (CY2027E) · all 8 rated companies, sorted descending · sector median 12.8x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 16.8x CORE · median 12.8x DISCOUNT · median 5.8x Sector median 12.8x WHAT SEPARATES THE TWO ENDS The forward gap remains wide. The premium end sits at 16.8x against 5.8x at the discount end. Because the EV / EBITDA lens is forward, expected growth is already credited; the remaining gap points to differing views of earnings durability. Specified capability supports confidence. Application depth, spec-in positions and qualification barriers can help buyers assess the resilience of revenue and margin through customer and input cycles. Mix quality sharpens the test. The key distinction is how much earnings come from formulated solutions versus commodity or tolling exposure, and how reliably price/mix protects the base.
- 0903 · VALUATION DRIVERS
Profitability Separates the Two Ends: Names Above the 18% Margin Line Carry 15.6x Against 8.5x Below It
This slide splits companies by revenue-growth and margin cohorts and shows the resulting median EV/EBITDA (CY2027E).
Profitability separates the two ends of the range clearly: names above the 18% margin line carry a median of 15.6x against 8.5x below it. Growth cohorts show a related, smaller split. These are associations in the data, not proof of cause — but the pattern is consistent enough to guide where to focus. So what: margin discipline appears to travel with valuation as closely as growth does, which reframes where management attention should sit.
Everything on this page
03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 18% Margin Line Carry 15.6x Against 8.5x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=4; higher-margin n=4; lower-margin n=4). Driver readings are NeuraCap views on the supplied data — association, not causation. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 4% · EBITDA-margin split at 18% Growth Separates the Two Valuation Groups Among eight names with estimates, the four at or above 4% growth sit at 12.9x, compared with 10.9x for the four below. This is an observed association, not evidence that growth alone accounts for the difference. Margin Adds an Important Second Test The names clearing both growth and profitability thresholds occupy a different valuation position from those clearing neither. Price/mix, plant utilisation and pass-through recovery help frame the quality of that margin. Commercial Proof Sits Inside the Pipeline Brief wins, vitality from recent formulations and share of key-account spend indicate whether current growth rests on repeatable co-creation and spec-in activity. Durability Depends on Revenue Quality Qualification barriers, customer retention and solutions mix can support resilience. Commodity exposure, crop volatility and customer concentration can weaken it.
- 1003 · SITUATION MAP
Higher Multiples Sit on Both Sides of the Growth Line
This slide maps companies on EV/EBITDA versus revenue growth against the sector medians to characterize situations.
Cutting the peer set on the sector median multiple and the covered median growth rate shows higher multiples on both sides of the growth line — not only among the fastest growers. These are observations about where names sit, not recommendations. So what: growth alone does not explain the valuation range, which means the next page's growth-and-margin view carries more of the answer.
Everything on this page
03 · SITUATION MAP Higher Multiples Sit on Both Sides of the Growth Line Cut on EV / EBITDA vs the sector median (12.8x) (rows) and revenue growth vs the covered median (4%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Momentum Above-median multiple · above-median revenue growth 2 names Sensient Technologies Corporation (SXT) · Balchem Corp (BCPC) These names combine above-line growth with an above-line multiple. Their position supports testing whether brief wins, customer adoption and margin quality can sustain the current standing. Premium Without Momentum Above-median multiple · below-median revenue growth 2 names International Flavors & Fragrances Inc. (IFF) · The Hain Celestial Group, Inc. (HAIN) These names hold an above-line multiple despite below-line growth. The valuation may reflect margin durability, portfolio quality or confidence in recovery, which makes retention and mix central tests. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 2 names Keurig Dr Pepper Inc. (KDP) · Westrock Coffee Company, LLC (WEST) These names show above-line growth while valuation remains below the sector reference. The commercial question is whether growth converts into durable margin and higher-quality mix. Rebuild Both Dimensions Below-median multiple · below-median revenue growth 2 names Nomad Foods Limited (NOMD) · Alto Ingredients, Inc. (ALTO) These names sit below both the growth and valuation references. Improvement depends on operating evidence around mix, cost absorption, pricing and customer retention.
- 1103 · GROWTH VS PROFITABILITY
Clearing Both Growth and Margin Bars Separates the Valuation Field
This slide plots the 8 companies with both estimates on revenue growth versus EBITDA margin, showing median EV/EBITDA per quadrant.
Among the 8 companies with both estimates, clearing both the growth and margin bars together separates the valuation field most cleanly. The quadrant that clears both sits well above the quadrant that clears neither. So what: this is the clearest single lens in the data for where a business is likely to sit in the valuation range.
Everything on this page
03 · GROWTH VS PROFITABILITY Clearing Both Growth and Margin Bars Separates the Valuation Field Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2026E, y-axis) · 8 companies with both estimates · cuts at the covered medians (4% growth, 18% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=3; margin-only n=1; growth-only n=1; neither n=3). Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 -5% 0% 5% 10% 15% 5% 10% 15% 20% 25% MARGIN ONLY median 16.2x BALANCED median 15.0x NEITHER median 6.9x GROWTH ONLY median 10.2x HAIN ALTO IFF NOMD BCPC WEST SXT KDP x: revenue growth (CY2027E) · y: EBITDA margin (CY2026E) HOW TO READ THIS Among eight names with estimates, three clear both the growth and 18% margin lines and sit at 15.0x; Balchem Corp (BCPC), Sensient Technologies Corporation (SXT) and Keurig Dr Pepper Inc. (KDP) are in this group. One name clears only the margin line and sits at 16.2x. One clears only the growth line and sits at 10.2x. The three below both lines sit at 6.9x, showing the lower valuation position associated with neither threshold being met. The neither median rests on 3 names and is lifted by HAIN at 14.9x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 0 of 8 names clear it.
- 1203 · THE AGENDA
A Company's Place in the Valuation Range Moves with Its Growth and Margin Record
This slide frames the questions an owner or acquirer should resolve given where growth and margin place a company in the range.
A company's place in the valuation range moves with its growth and margin record, and that record raises specific questions for any owner or acquirer to resolve. These are NeuraCap observations framed as questions, not recommendations. So what: the next section grounds those questions in what buyers have actually paid for in this sector.
Everything on this page
03 · THE AGENDA A Company's Place in the Valuation Range Moves with Its Growth and Margin Record NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Move Further into Specified Solutions Prioritise formulation work where qualification, on-label approval and organoleptic performance support durable customer positions. What changes the answer: Brief wins convert into repeat orders without giving back price/mix. Build Breadth Around Customer Briefs Add capabilities that let application teams solve more of a customer’s taste, color, texture and nutrition requirements. What changes the answer: Cross-capability briefs raise share of key-account spend and shorten the path to launch. Protect Margin Through the Cycle Tighten pass-through mechanics, campaign planning and fixed-cost absorption while reducing exposure to volatile commodity streams. What changes the answer: Margin holds as input costs, customer inventories and plant utilisation change. Use Capital Where Capability Compounds Compare internal build, partnership and acquisition routes for application labs, encapsulation, natural colors and regional supply assurance. What changes the answer: The chosen route clears customer qualification faster and supports repeatable commercial returns.
- 13SECTION 04
04
This divider introduces the section on precedent transactions.
The transaction record spans platform acquisitions, capability additions and portfolio reshaping, and it favors buyers with asset-specific conviction. So what: the case studies that follow show what buyers priced and why.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Favour Buyers with Asset-Specific Conviction The transaction record spans platform acquisitions, capability additions and portfolio reshaping. 04 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13
- 1404 · DEAL CASE STUDIES
Precedent Transactions Suggest Buyers Price Strategic Fit Across a Wide Range
This slide walks through a precedent transaction with disclosed terms as a case study, one of 15 transactions with disclosed terms.
This case study is one of 15 transactions with disclosed terms, told with the strategic logic behind the deal alongside the multiple paid on LTM financials at announcement. Deal multiples sit on a different basis than the CY2027E public multiples shown earlier, so no spread between the two is claimed. So what: precedent deals show buyers pricing strategic fit and capability directly, which is a distinct signal from where public markets price the same names today.
Everything on this page
04 · DEAL CASE STUDIES Precedent Transactions Suggest Buyers Price Strategic Fit Across a Wide Range 1 of 15 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; no evidence record); figures are shown as recorded in the filing. 27 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Feb-2026 $1.1B 2786694 Alberta Ltd. 2786694 Alberta Ltd. agreed to acquire SunOpta Inc. as a complete operating platform. EV / LTM revenue 1.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests conviction in SunOpta Inc. as a standalone platform rather than a disclosed capability bolt-on. The buyer’s recorded identity does not support a more specific operating rationale. HOW THE TARGET WAS VALUED SunOpta Inc. was valued at $1.1B and 1.4x EV / Revenue. This is a revenue benchmark and should be read separately from the forward EV / EBITDA lens used for the peer set.
- 15SECTION 05
05
This divider introduces the section on strategic implications.
The practical agenda is to deepen specified solutions while protecting the earnings base — strengthening the operating proof behind mix, margin and retention. So what: the next page turns the data into a working agenda for owners, management and boards.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Strengthen the Operating Proof Behind Mix, Margin and Retention The practical agenda is to deepen specified solutions while protecting the earnings base. 05 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15
- 1605 · STRATEGIC IMPLICATIONS
Where Revenue Is Durable and Margin Defensible, Valuations Sit Nearer the Top of the Range
This slide sets out the strategic questions the data raises for the next twelve months.
Where revenue is durable and margin is defensible, valuations sit nearer the top of the range — and that pattern points to a clear agenda: deepen specified solutions, link growth to margin quality, and allocate capital where capability compounds. These are NeuraCap views grounded in the analysis shown, not recommendations to buy or sell any security. So what: the agenda gives owners, management teams and boards a shared starting point for the conversations this data raises.
Everything on this page
05 · STRATEGIC IMPLICATIONS Where Revenue Is Durable and Margin Defensible, Valuations Sit Nearer the Top of the Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Make Solutions Mix the Operating Priority Shift commercial attention toward specified formulations, co-creation and repeat brief wins. Protect the customer positions where qualification and on-label approval make replacement harder. FOR MANAGEMENT TEAMS Link Growth to Margin Quality Separate volume recovery from price/mix and new-formulation adoption. Align plant loading, raw-material recovery and account choices with the earnings base the market can sustain. FOR BOARDS Allocate Capital Around Capability Gaps Test build-versus-buy choices against customer access, qualification time, technical depth and regional supply assurance. Favour moves that strengthen the solutions core without adding unmanaged capital drag.
- 17SECTION 06
06
This divider introduces the appendix covering the full comparable universe, methodology and sources.
The appendix carries the comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. So what: any figure in this deck can be traced back to its source from here.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17
- 1806 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier
This slide lists all 8 rated companies and 4 unrated companies with EV/EBITDA (CY2027E), grouped by valuation tier.
All 8 rated companies sit in this table alongside the 4 names without an eligible multiple, grouped by valuation tier against the 12.8x sector median. Every row here links back to its underlying source. So what: this is the full rated universe behind every multiple quoted earlier in the deck.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (12.8x); amber marks below · 8 rated companies; 4 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 8 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥15.3x · median 16.8x · 2 companies Balchem Corp BCPC Specialty food ingredient chemistry — colors, enzymes… $5.6B 17.4x 6% 27% 32 International Flavors & Fragrances Inc. IFF Specialty food ingredient chemistry — colors, enzymes… $27.7B 16.2x 1% 20% 23 CORE — 9.3x–15.3x · median 12.8x · 4 companies Sensient Technologies Corporation SXT Specialty food ingredient chemistry — colors, enzymes… $6.2B 15.0x 13% 20% 33 The Hain Celestial Group, Inc. HAIN Adjacent: packaged food brand owners (formulation… $596M 14.9x -5% 8% -1 Keurig Dr Pepper Inc. KDP Adjacent: branded non-alcoholic beverages (ingredient… $77.8B 10.7x 14% 24% 38 Westrock Coffee Company, LLC WEST Adjacent: packaged food brand owners (formulation… $1.3B 10.2x 8% 8% 18 DISCOUNT — <9.3x · median 5.8x · 2 companies Nomad Foods Limited NOMD Adjacent: packaged food brand owners (formulation… $3.9B 6.9x 2% 16% 18 Alto Ingredients, Inc. ALTO Specialty food ingredient chemistry — colors, enzymes… $357M 4.7x 0% 7% 8
- 1906 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This slide lists precedent transactions with disclosed terms, newest first.
These are the transactions with disclosed terms, newest first, with multiples on LTM financials at announcement where disclosed. Deal values link back to the underlying filing. So what: this is the primary evidence behind the transaction range discussed earlier in the deck.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 15 transactions with disclosed terms in this tier (42 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; no evidence record); figures are shown as recorded in the filing. 27 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters May-2026 CVC Capital Partners → Food Ingredients business (unit of Food Ingredients business segment) $4.3B n/a n/a CVC Capital Partners agreed to acquire Food Ingredients business (unit of Food Ingredients business segment). The transaction highlights continuing interest in separable ingredient operations. Feb-2026 2786694 Alberta Ltd. → SunOpta Inc. $1.1B 1.4x n/a 2786694 Alberta Ltd. agreed to acquire SunOpta Inc. The transaction provides a recent benchmark for a complete operating platform. Jan-2023 Irca S.p.A. → Kerry Group plc n/a n/a 12.2x Irca S.p.A. agreed to acquire Kerry Group plc. The pairing suggests interest in extending an established ingredient offering. Oct-2022 Orkla Food Ingredients → Denali Ingredients n/a n/a 13.9x Orkla Food Ingredients agreed to acquire Denali Ingredients. The transaction suggests a strategic fit between an ingredient platform and an adjacent capability. Jun-2022 Horizon Therapeutics Plc → Natra S.A. n/a 8.3x n/a Horizon Therapeutics Plc agreed to acquire Natra S.A. The disclosed valuation provides a transaction reference, while the strategic fit should be assessed on the recorded parties. Dec-2019 International Flavors & Fragrances Inc. → DuPont Nutrition & Biosciences, Inc. $45.4B n/a n/a International Flavors & Fragrances Inc. (IFF) agreed to acquire DuPont Nutrition & Biosciences, Inc. The combination brought flavor, nutrition and bioscience capabilities into a broader platform. Dec-2019 Act II Global Acquisition Corp. → Whole Earth Brands (Merisant Co. and MAFCO Worldwide) n/a n/a 8.2x Act II Global Acquisition Corp. agreed to acquire Whole Earth Brands (Merisant Co. and MAFCO Worldwide). The transaction connected a public acquisition vehicle with a branded sweetener platform. Oct-2019 One Rock Capital Partners → Innophos Holdings, Inc. n/a n/a 7.8x One Rock Capital Partners agreed to acquire Innophos Holdings, Inc. The transaction is consistent with sponsor interest in technical, application-oriented businesses. May-2018 IFF → Frutarom n/a n/a 20.3x International Flavors & Fragrances Inc. (IFF) agreed to acquire Frutarom. The combination suggests strategic interest in a broader flavor and ingredient offering.
- 2006 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This slide continues the list of precedent transactions with disclosed terms, newest first.
The list continues here, completing the set of transactions with disclosed terms behind the case studies shown earlier. So what: together these two pages hold the full disclosed-terms record supporting the transaction range.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 15 transactions with disclosed terms in this tier (42 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; no evidence record); figures are shown as recorded in the filing. 27 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2018 Givaudan → Naturex n/a n/a 22.8x Dec-2017 Nestlé S.A. → Atrium Innovations Inc. n/a n/a 14.0x Sep-2016 B&G Foods, Inc. → ACH Food Companies, Inc. (spices business) n/a n/a 9.4x Value shown as recorded in the filing; deal value unit unresolved. Aug-2016 Investors Group Inc. → Vitaco Holdings Limited n/a n/a 14.7x Dec-2012 Univar Inc. → Mangablend, Inc. n/a n/a 7.9x Dec-2010 Royal DSM N.V. → Martek Biosciences Corporation n/a 8.8x 8.8x
- 2106 · METHODOLOGY
Sources, Assumptions and Data Quality
This slide explains the report's sources, assumptions and data-quality treatment.
Every figure in this report links to the filing, consensus estimate or market price it was taken from, and where a figure has no link, the appendix names its source and the basis on which it was read. So what: a client can verify any number in this deck against something they can open themselves.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Food Ingredients and Flavorings and it clears the coverage gate with 8 of 12 companies (67%). EV / Revenue, P / E are carried as a cross-check. The set earns: 8 of the 9 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 17 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 485 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (484) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 22
Higher Forward Valuations Sit with Growth, Margin and Specified-Solutions Quality.
This is the closing slide restating that higher forward valuations sit with growth, margin and specified-solutions quality.
Higher forward valuations sit with growth, margin and specified-solutions quality — that is the throughline across every section of this report. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace. So what: this closing line is the one takeaway worth carrying into the next conversation about where to invest attention and capital.
Everything on this page
Higher Forward Valuations Sit with Growth, Margin and Specified-Solutions Quality. NeuraCap AI — Food Ingredients and Flavorings Coverage September 2026 · Prepared by NeuraCap AI · Confidential Food Ingredients and Flavorings Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22
Sources and methodology
This report covers Food Ingredients and Flavorings (Consumer Staples › Food, Beverage and Tobacco › Food Ingredients and Flavorings) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Food Ingredients and Flavorings according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alto Ingredients, Inc. (ALTO), Balchem Corp (BCPC), Beyond Meat, Inc. (BYND), Domino's Pizza, Inc. (DPZ), The Hain Celestial Group, Inc. (HAIN), International Flavors & Fragrances Inc. (IFF), Keurig Dr Pepper Inc. (KDP), The Kraft Heinz Company (KHC), Nomad Foods Limited (NOMD), Sensient Technologies Corporation (SXT), Vital Farms, Inc. (VITL), Westrock Coffee Company, LLC (WEST). The market map groups them by business vertical — Adjacent: packaged food brand owners (formulation customers): 5 companies (KHC, NOMD, WEST, HAIN, BYND); Specialty food ingredient chemistry — colors, enzymes and texturants: 4 companies (IFF, SXT, BCPC, ALTO); Adjacent models: 3 companies (KDP, DPZ, VITL). 8 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Food Ingredients and Flavorings (Consumer Staples › Food, Beverage and Tobacco › Food Ingredients and Flavorings) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Food Ingredients and Flavorings according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alto Ingredients, Inc. (ALTO), Balchem Corp (BCPC), Beyond Meat, Inc. (BYND), Domino's Pizza, Inc. (DPZ), The Hain Celestial Group, Inc. (HAIN), International Flavors & Fragrances Inc. (IFF), Keurig Dr Pepper Inc. (KDP), The Kraft Heinz Company (KHC), Nomad Foods Limited (NOMD), Sensient Technologies Corporation (SXT), Vital Farms, Inc. (VITL), Westrock Coffee Company, LLC (WEST). The market map groups them by business vertical — Adjacent: packaged food brand owners (formulation customers): 5 companies (KHC, NOMD, WEST, HAIN, BYND); Specialty food ingredient chemistry — colors, enzymes and texturants: 4 companies (IFF, SXT, BCPC, ALTO); Adjacent models: 3 companies (KDP, DPZ, VITL). 8 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
17 records failed a validation gate and never feed a statistic in this report (1 excluded from universe; 16 excluded from aggregate). Each exclusion, with its reason: INGR — The ticker INGR carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · ALTO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BYND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BYND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BYND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HAIN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HAIN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · IFF — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · KHC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · VITL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WEST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WEST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WEST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)
Primary valuation basis and how it was chosen
Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Food Ingredients and Flavorings and it clears the coverage gate with 8 of 12 companies (67%). EV / Revenue, P / E are carried as a cross-check. The set earns: 8 of the 9 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 8 of 12 companies; EV / rEVenue: 12 of 12 companies; P/E: 11 of 12 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 1 company shows a non-meaningful P / E denominator and is excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥15.3x, Core 9.3x–15.3x, Discount <9.3x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 12.8x = median(ev_ebitda CY2027E) (8 rated companies) · 16.8x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 12.8x = median(ev_ebitda CY2027E) within Core tier (n=4) · 5.8x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 12.9x = median(ev_ebitda CY2027E) | growth ≥ 4% (n=4) · 10.9x = median(ev_ebitda CY2027E) | growth < 4% (n=4) · 15.6x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 18% (n=4) · 8.5x = median(ev_ebitda CY2027E) | EBITDA margin < 18% (n=4) · 20% = median Rule of 40 score (revenue growth + EBITDA margin) (n=8) · 15.0x = median(ev_ebitda CY2027E) within balanced quadrant (n=3) · 16.2x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=1) · 10.2x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=1) · 6.9x = median(ev_ebitda CY2027E) within neither quadrant (n=3) · 14.9x = ev_ebitda CY2027E for HAIN (quadrant outlier)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Food Ingredients and Flavorings recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 42 transactions were recorded for this industry; 15 are shown. 27 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 18 × deal value unit unresolved; 29 × no evidence record; 5 × divestiture roles reassigned. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 489 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- The Kraft Heinz (KHC) (sec.gov)
- Westrock Coffee (WEST) (sec.gov)
- The Hain (HAIN) (sec.gov)
- Beyond Meat (BYND) (sec.gov)
- International (IFF) (sec.gov)
- Sensient (SXT) (sec.gov)
- Balchem (BCPC) (sec.gov)
- Alto Ingredients (ALTO) (sec.gov)
- Keurig Dr Pepper (KDP) (sec.gov)
- Vital Farms (VITL) (sec.gov)
- $1.1B (sec.gov)
- $4.3B (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 8.3x (sec.gov)
- $45.4B (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- sec.gov (484) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Consumer Staples
- M&A Update · 29 September 2026Food Retail M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Food Retail Sector Outlook — September 2026
- M&A Update · 29 September 2026Frozen Foods M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Frozen Foods Sector Outlook — September 2026
Want this analysis for a company in Food Ingredients and Flavorings?
Company valuation reports run the same method against a single business — public or private.
